Hims & Hers Health: Navigating Volatility, Opportunities, and a Cautious "Buy" Rating

Hims & Hers Health, Inc. (HIMS) faces significant market volatility, regulatory scrutiny, and legal challenges, particularly concerning its weight-loss drug offerings. Despite these hurdles, the company's recent Q4 results showcased a 28% year-over-year revenue growth to $617.8 million and an adjusted EBITDA of $66.3 million. However, subscriber growth and Q1 guidance were impacted by headwinds from GLP-1 drugs. The company is actively pursuing international expansion and lab initiatives as key growth drivers, aiming for over $1 billion in annual international revenue and $1.3 billion in adjusted EBITDA by 2030. Given the high-risk, high-reward nature, a cautious and gradual investment approach is recommended.